Please join us for the second session in our seminar series - a focus on the Creative Destruction Lab and the leadership role it took early in the pandemic, convening innovators to tackle the new issues and challenges suddenly front and centre for the entire population.
The session will begin with an overview of the CDL from Sonia Sennik, Executive Director. This will be followed by a panel discussion featuring Sonia Sennik, Shana Kelly on her experiences with start-up ARMA Biosciences in the CDL Health stream in Toronto, and Kourosh Saeb-Parsy and Jurgen Riedel on their experiences with start-up Oxford Immune Algorithmics, part of the CDL Recovery stream in UK.
Panelists:
- Shana Kelley, University Professor, University of Toronto and co-founder and CEO of ARMA Biosciences
- Jurgen Riedel, Co-Founder and CTO, Oxford Immune Algorithmics
- Kourosh Saeb-Parsy, Chief Medical Officer, Oxford Immune Algorithmics
- Sonia Sennik, Executive Director, Creative Destruction Lab
In conversation with Alberto Galasso, Professor of Strategic Management, Rotman Chair in Life Sciences Commercialization
About Our Speakers:
Alberto Galasso is a Professor of Strategic Management at the University of Toronto, where he holds the Rotman Chair in Life Sciences Commercialization. He is Research Associate at the National Bureau of Economic Research (NBER) and Research Fellow at the Centre for Economic Policy Research (CEPR). He serves as co-editor for the Journal of Economics and Management Strategy, as associate editor for the Journal of Industrial Economics and the International Journal of Industrial Organization, and as member of the editorial board for the Strategic Management Journal. His research agenda focuses on the determinants of innovative activity, the management of innovation and the functioning of markets for technology.
Dr. Shana Kelley is a University Professor at the University of Toronto and a member of the Departments of Chemistry, Biochemistry, Pharmaceutical Sciences and Biomedical Engineering. Dr. Kelley received her Ph.D. from the California Institute of Technology and was a NIH postdoctoral fellow at the Scripps Research Institute. The Kelley research group works in a variety of areas spanning biophysical/bioanalytical chemistry, chemical biology and nanotechnology, and has pioneered new methods for tracking molecular and cellular analytes with unprecedented sensitivity. Dr. Kelley’s work has been recognized with a variety of distinctions, including being named one of “Canada’s Top 40 under 40”, a NSERC E.W.R. Steacie Fellow, the 2011 Steacie Prize, and the 2016 NSERC Brockhouse Prize. She has also been recognized with the ACS Inorganic Nanoscience Award, the Pittsburgh Conference Achievement Award, an Alfred P. Sloan Research Fellowship, a Camille Dreyfus Teacher-Scholar award, a NSF CAREER Award, a Dreyfus New Faculty Award, and was also named a “Top 100 Innovator” by MIT’s Technology Review.
Oxford Immune Algorithmics Co-founder & CTO, Dr. Jurgen Riedel, is a theoretical physicist (PhD) by training, having conducted research into black holes and dark matter, quantum gravity and boson stars, as well as cellular automata and complexity science. His business expertise encompasses extensive knowledge of database systems, data migration, business intelligence, analytics, data science, data visualisation, data governance and compliance, and is an expert in data analytics and machine learning with more than 25 years of industry experience in 3 continents. He created analytics platforms to manage assets of more than $2B in private & investment banking, and held positions in the automobile, manufacturing, and energy industries, including UBS, Citibank, Volkswagen, Zalando, Munich RE, Eon, and, most recently, Rabobank.
Kourosh Saeb-Parsy is Professor of Transplantation at University of Cambridge, UK. He is an abdominal organ transplant surgeon and research group leader at the university of Cambridge. The focus of his research is the immune response to transplanted organs, regenerative cellular therapies and cancer. He has extensive experience in working with commercial organisations to advance new technologies and discoveries toward patient benefit. He is the Chief Medical Officer at Oxford Immune Algorithmics.
Sonia Sennik is the Executive Director of Creative Destruction Lab (CDL), a seed-stage program for massively scalable, science-based companies. Sonia is responsible for the CDL’s strategic, operational and programmatic leadership, coordination and oversight to ensure the success of the Lab and its ventures across ten university-based locations in Canada, US, UK and France. The organization operates sites at the University of Toronto, University of Oxford, Georgia Tech, HEC Paris, University of Wisconsin-Madison, University of British Columbia, University of Montreal, University of Calgary, University of Washingon, and Dalhousie University. Sonia is also the Executive Director of the CDL Rapid Screening Consortium, a not-for-profit organization focused on developing a cost-effective system for reopening the economy during the COVID-19 pandemic.
Watch Video Recording here